Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 4, 2003, Pages 173-179

  Lee, Kyu Eun ^a   Lee, Hyuk Joon ^a   Kim, Yoon Ho ^a   Yu, Hang Jong ^b   Yang, Han Kwang ^a   Kim, Woo Ho ^a   Lee, Kuhn Uk ^a   Choe, Kuk Jin ^a   Kim, Jin Pok ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

c erbB 2; Gastric cancer; nm23; p53; Prognostic factor; Proliferating cell nuclear antigen (PCNA)

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; TRANSCRIPTION FACTOR;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GASTRECTOMY; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STOMACH CANCER; SURGICAL TECHNIQUE; TISSUE DISTRIBUTION; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038470907     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg039     Document Type: Article

References (40)

1. Cheung LY, Delcore R. Gastric cancer. In: Townsend CM, editor. Sabiston Textbook of Surgery. 16th ed. Philadelphia: W.B. Saunders 2001;855-65.
2. Annual Report on the Cause of Death Statistics (Based on Vital Registration). Seoul: National Statistical Office 2000.
3. Central Cancer Registry in Korea. Annual Report of the Central Cancer Registry in Korea. Seoul: Ministry of Health and Welfare 2000.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49:1991.
5. Milner J, Watson JV. Addition of fresh medium induces cell cycle and conformational changes in p53, a tumor suppressor protein. Oncogene 1990;5:1683-90.
6. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produced a gene product that forms an HSP70-p53 complex with an altered half-life. Mol Cell Biol 1988;8: 531-9.
7. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, et al. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993;53:2614-7.
8. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 expression in gastric and colorectal carcinoma. Br J Cancer 1992;66: 558-62.
9. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasizing to lymph nodes. Br J Cancer 1993;67:589-93.
10. Seruca R, David L, Holm R, Nesland JM, Fangan BM, Castedo S, et al. p53 mutations in gastric carcinomas. Br J Cancer 1992;65:708-10.
11. Mönig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: Clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7.
12. Ochiai A, Yamauchi Y, Hirohashi S. p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 1996;69:28-33.
13. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
14. Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepato-Gastroenterology 1997;44:604-9.
15. Sasano H, Date F, Imatami A, Asaki S, Nagura H. Double immunostaining for c-erbB2 and p53 in human stomach cancer cells. Hum Pathol 1993;24: 584-9.
16. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor-metastatic potential. J Natl Cancer Inst 1988;80:200-3.
17. Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, et al. Low nm23/NDP kinase protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991; 139:245-50.
18. Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res 1992; 52:6088-91.
19. Nakayama T, Ohtsuru A, Nakao K, Shima M, Nakata K, Watanabe K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992;84:1349-54.
20. Ayhan A, Yasui W, Yolozaki H, Kitadai Y, Tahara E. Reduced expression of nm23 protein is associated with advanced tumor stage and distant metastases in human colorectal carcinomas. Virchows Arch B Cell Pathol 1993;63:213-8.
21. Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: Association with tumor progression in Clara cell type. Jpn J Cancer 1994;85:840-6.
22. Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y, et al. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: An association with lymph node metastasis and tumor invasion. Clin Exp Metastasis 1993;11:151-8.
23. Kodera Y, Isobe K, Yamauchi M, Kondoh K, Kimura N, Akiyama S, et al. Expression of nm23-H1 RNA levels in human gastric cancer tissues. Cancer 1993;73:259-65.
24. Nakayama H, Yasui W, Yokozaki H, Tahara E. Reduced expression of nm23 protein is associated with metastasis of human gastric carcinomas. Jpn J Cancer Res 1993;84:184-90.
25. Müller W, Schneiders A, Hommel G, Gabbert H. Expression of nm23 in gastric carcinoma. Association with tumor progression and poor prognosis. Cancer 1998;83:2481-7.
26. Waseen NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990;96:121-9.
27. Lee SH, Hurwitz J. Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen and activator 1. Proc Natl Acad Sci USA 1990;87:5672-6.
28. Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-74.
29. Konno S, Takebayashi Y, Aiba M, Akiyama S, Ogawa K. Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric cancer. Cancer Lett 2001;166: 103-11.
30. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumor angiogenesis and tumor cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995;72:319-23.
31. He XB, Ii K, Muguruma N, Hayashi S, Ito S. Expression of proliferating cell nuclear antigen in biopsy and autopsy specimens of gastric carcinoma. J Med Invest 1998;44:149-53.
32. Mangham DC, Rowlands DC, Newbold KM, Reynolds GM, Fielding JW, Hallissey MT. Expression of proliferating cell nuclear antigen in gastric carcinoma: No evidence for prognostic value. J Clin Pathol 1994;47:473-4.
33. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
34. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
35. Jain S, Filipe MI, Gullick WJ, Linehan J, Moris RW. c-erbB-2 protooncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archive material. Int J Cancer 1991;48: 668-71.
36. Falck VG, Gullick WJ. c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 1989;159: 107-11.
37. Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H. erbB2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994;115:349-54.
38. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991;51:1034-8.
39. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, et al. Overexpression of c-erbB-2 protein in gastric cancer: Its correlation with long-term survival of patients. Cancer 1993;72:3179-84.
40. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8.